多西他赛联合希罗达治疗晚期乳腺癌的临床分析(2)
 |
| 第1页 |
参见附件。
[2] 孙燕，石远凯.临床肿瘤内科学手册[M].第5版.北京：人民卫生出版社，2007：425-435，811.
[3] Brunello A，Roma A，Falci C，et al.Chemotherapy and targeted agents for elderly women with advanced breast cancer [J].Recent Patents Anticancer Drug Discov，2008，3(3)：187-201.
[4] Schuller J，Cassidy J，Dumont E，et al.Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients[J].Cancer Chemother Pharmacol，2000，45：291.
[5] 姜丽娜，丁世英，熊慧英，等.胸苷磷酸化酶在瘤组织中表达的研究[J].中华肿瘤杂志，2004，26(5)：297-298.
[6] Koukourakis GV，Kouloulias V，Koukourakis MJ，et al.Efficacy of the oral fluorouracil pro-drug capecitabine in cancer treatment：a review [J].Molecules，2008，13(8)：1897-922.
[7] Kaori Fujimoto-Ouchi，Yutaka Tanaka，Takeshi Tominaga.Schedule Dependency of Antitumor Activity in Combination Therapy with Capecitabine/5/-Deoxy-5-fluorouridine and Docetaxel in Breast Cancer Models[J].Clin Cancer Res，2001，7：1079-1086.
[8] 徐兵河，赵龙妹，袁破，等.多西紫杉醇联合卡培他滨治疗蒽环类药性晚期乳腺癌的初步临床结果[J].癌症进展，2004，2(1)：18
[9] 马婕，徐正丰.多西他赛联合希罗达治疗蒽环类耐药转移性乳腺癌临床观察[J].长江大学学报(自然科学版)，2011，1：148-150，285.
[10] Karachaliou N，Ziras N，Syrigos K，et al. A multicenter phase II trial of docetaxel and capecitabine as salvage treatment in anthracycline-and taxane-pretreated patients with metastatic breast cancer[J]. Cancer Chemother Pharmacol，2012，70(1)：169-76.
[11] Young SD，Lafrenie RM，Clemons MJ.Phase ii trial of a metronomic schedule of docetaxel and capecitabine with concurrent celecoxib in patients with prior anthracycline exposure for metastatic breast cancer[J].Curr Oncol，2012，19(2)：e75-83.
(收稿日期：2013-01-16)
您现在查看是摘要介绍页，详见PDF附件。